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Abstract
A 56 year-old man with severe left ventricular dysfunction was admitted due to exacerbation of chronic heart failure with 
reduced left ventricular ejection fraction. During hospitalisation, standard heart failure treatment was used, but with 
a modification of pharmacotherapy to address concurrent conditions including diabetes. Here we discuss this case and 
the current state of knowledge regarding the beneficial effects of empagliflozin.
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Introduction
Guidelines from the European Society of Cardiology (ESC) 
[1] state that heart failure (HF) is a set of typical secon-
dary symptoms including shortness of breath, swelling of 
the lower limbs, and reduced tolerance to strain. These 
symptoms can be accompanied by neck vasodilation, lung 
crackles, and peripheral oedema caused by disturbances in 
cardiac structure and/or function, causing reduced cardiac 
output and/or increased intracardiac pressure at rest and 
during strain. Symptom intensity is based on the New York 
Heart Association’s classification, an important measure 
for assessing patients with heart failure, even though it 
correlates only weakly with most of the parameters relevant 
to left ventricular function [1]. It is recognised that any 
exacerbation of symptoms in the NYHA classification is 
linked to higher risks of hospitalisation and death [2, 3].
Moreover, concurrent conditions can exacerbate symp-
toms of HF, thus increasing the risk of hospitalisation and 
death due to worsening HF. According to ESC guidelines, 
the additional presence of diabetes is linked to reduced 
physical function and a worse prognosis. Studies by Fra-
mingham [4] showed that the risk of HF in a diabetic patient 
is almost 2.4 times higher in men, and 5 times higher in 
women, compared to non-diabetic individuals. It was also 
shown that a 1% increase in glycated haemoglobin causes 
an 8% increase in the risk of heart failure, irrespective of 
age, presence of coronary heart disease, blood pressure, 
or obesity [5]. 
In addition, the relationship between heart failure 
and diabetes is a double-edged sword, because diabetic 
patients are at greater risk of developing heart failure due 
to processes taking place in the cardiovascular system. 
Hyperinsulinaemia, hyperglycaemia, acidosis and insulin 
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resistance are factors causing heart remodelling by mo-
difying cellular pathways in cardiomyocytes. Two dominant 
processes in the diabetic heart have been identified. The 
first is left ventricular (LV) dysfunction caused mostly by 
the intoxication of cardiomyocytes by the substrates of 
incorrect metabolic processes taking place in the cell, 
including storage of free fatty acids, leading to lipidosis of 
heart cells, altered intra- and extracellular metabolite ba-
lance, and cardiomyocyte electrophysiological properties. 
In this respect, one should also consider modifications to 
metabolic pathways, mitochondrial dysfunction and oxidati-
ve stress, and damage to the vascular endothelium, which 
can all lead to heart muscle necrosis. The second process 
is that of chronic inflammation, which is associated with 
increased collagen synthesis and fibrosis [6].
Diabetic patients commonly have systolic and diastolic 
dysfunction and arrhythmia. Diabetic polyneuropathy and 
the involvement of the sympathetic nervous system, along 
with fibrotic changes in the heart and reduced ejection 
function, predispose these patients to the development of 
arrhythmias, including life-threatening ventricular arrhyth-
mias.
Case description
A 56 year-old male was admitted with class III heart failure 
according to the NYHA, i.e. shortness of breath, oedema 
of the lower limbs up to the knees, and blood pressure of 
135/85 mm Hg. The patient was warm and damp as per 
Forrester’s classification. 
Patient history:
 — severe systolic dysfunction of the LV;
 — implantation of a cardiac resynchronisation therapy 
defibrillator (CRT-D);
 — moderate aortic stenosis;
 — chronic coronary heart disease – cardiac infarction with 
ST-segment elevation in the wall of the lower and right 
ventricles treated with two unsuccessful attempts at re-
vascularisation of the right coronary artery, complicated 
by transient third degree atrioventricular block; follow-
ing the infarction, ST-segment was no longer elevated, 
and was treated with angioplasty of the circumflex 
branch of the coronary artery with implantation of two 
drug-eluting stent (DES) stents;
 — arterial hypertension (blood pressure max. 170/90 mm Hg);
 — type 2 diabetes currently treated with metformin 
therapy;
 — mixed hyperlipidemia currently treated with statins;
 — obesity [body mass index (BMI) 40.56 kg/m2, height: 
172 cm, body weight: 120 kg], metabolic syndrome;
 — paroxysmal atrial fibrillation.
Laboratory studies found significant deviations from 
the norm in the following parameters: reduced kidney 
parameters, increased levels of glucose, triglycerides and 
N-terminal pro-B-type natriuretic peptide (NT-proBNP), 
though, due to the patient’s obesity, these parameters 
are consistent with the other symptoms presented by the 
patient (Table 1 — stay 1).
On admission to the hospital, an electrocardiogram 
(ECG) found a regular sinus rhythm of 90/min with type 
atrial synchronous biventricular pacing (AS-BiVP) stimula-
tion, and correct stimulation and sensing was found.
During hospitalisation, another ECG confirmed severe 
systolic dysfunction of the left ventricle [left ventricular 
ejection fraction (LVEF) 24%, left ventricular end-diastolic 
diameter (LVEDd) 65 mm, end-diastolic volume/exhalation 
volume [EDV/EV] 250/190 mL) with segmental dysfunction 
of contractility of the lower and back walls and moderate 
aortic stenosis and impaired contractile function of the 
enlarged right ventricle [tricuspid annular plane systolic 
excursion (TAPSE) 16 mm, S’ 9 cm/s, right ventricular 
diameter proximal (RVD prox) 35 mm].
During hospitalisation, the patient received intensive 
intravenous diuretics and standard therapy for HF was 
maintained [angiotensin-converting enzyme (ACE) inhibi-
tors, beta-blockers, mineralocorticoid receptor antagonists 
(MRA)]. The patient’s general condition and heart failure 
symptoms improved. A 6-minute walk test (6-MWT) was 
conducted, in which the patient achieved 290 m.
A control coronary angiography showed a good re-
sponse to the stent implanted in the circumflex branch 
and the amputated right coronary artery, creating collateral 
circulation. The patient qualified for further conservative 
treatment.
The patient’s MAGIC (Meta-Analysis Global Group in 
Chronic Heart Failure) prognostic score was found to be 
serious — 26 points, with 1-year mortality of 17.5% and 
3-year mortality of 39.7%. Prior to being discharged, the 
patient’s diabetes treatment was modified with the addition 
of empagliflozin to metformin.
The patient was discharged to outpatient care on the 
following medications: dabigatran 2 × 110 mg, atorvastatin 
20 mg, bisoprolol 7.5 mg, amiodarone 200 mg, ramipril 
5 mg, lercanidipine 10 mg, eplerenone 50 mg, pantopra-
zole 20 mg, empagliflozin 10 mg, torasemide 10 mg, and 
metformin 3 × 850 mg.
Two months after hospitalisation, during a follow-up visit 
at a cardiology clinic, a stable clinical state was observed 
with a satisfactory (NYHA class II) strain tolerance, and 
with NT-proBNP of 153 pg/dL. The CRT found a significant 
reduction in obstruction, corresponding with improved 
clinical outcomes.
After four months, the patient was once again hos-
pitalised due to an exacerbation of HF, with NT-proBNP 
of 1,586 pg/mL, and during this stay he was included in 
a sacubitril/valsartan treatment programme at a dosage 
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of 97/103 mg. For more than a year he was clinically 
stable and did not require further hospitalisation due to 
HF exacerbations.
The next hospitalisation was due to an airway infection, 
during which his HF worsened. The patient was hospitalised 
in the regional department for internal medicine due to 
orthopnea, coughing up yellow-grey fluid over the course 
of the airway infection, and increasing lower limb oedema. 
While being admitted, a urine test detected glycosuria, with 
venous blood glucose levels of 149 mg/dL (Table 1 — stay 2), 
which was considered to be the result of empagliflozin 
treatment. Following antibiotic treatment and intravenous 
diuretics, the patient was discharged with clinical improve-
ments. Empagliflozin treatment was discontinued.
After a visit to a cardiology clinic three months after the 
previous hospitalisation, due to a notable increase in body 
weight (around 10 kg), exacerbation of lower limb oedema 
up to the knees, and worsening of HF up to NYHA Class III/IV, 
 the patient was referred to the hospital with acute heart 
failure. Results of laboratory studies are shown in Table 1 — 
stay 3. Full treatment for cardiac failure was given, including 
intravenous diuretics and levosimendan infusion, resulting 
in significant clinical improvement, reduced body weight 
and decreased oedema and breathlessness. Following 
discharge, due to a resting heart rate (HR) above 75/min, 
additional treatment with the beta-blocker ivabradine was 
prescribed. Glycated haemoglobin was 9.10%, suggestive of 
unsatisfactory levels of glycaemia in the last three months 
in the range of 11.8 mmol/L (212 mg/dL).
For this patient, previous non-pharmacological treat-
ments were unfortunately unsuccessful. It should be 
emphasised that morbid obesity (BMI 40.56 kg/m2) is 
linked to hyperinsulinemia, leading to the activation of the 
renin–angiotensin–aldosterone (RAA) system and renewed 
HF exacerbations. On the other hand, treating this type of 
patient with insulin, which causes sodium retention with 
simultaneous decrease of glycosuria, can increase fluid 
retention and would therefore not be an optimal solution. 
After the patient became clinically stable during the peri-
discharge period, empagliflozin treatment was resumed. In 
a 6-MWT, the patient achieved a distance of 330 m. The pa-
tient was given full information regarding HF and diabetes.
The patient was discharged home with non-pharma-
cological treatment suggestions and with the following 
recommendations of pharmacotherapy: dabigatran 2 × 
× 110 mg, sacubitril/valsartan 2 × 97/103 mg, ivabradine 
2 × 5 mg, atorvastatin 80 mg, bisoprolol 10 mg, amio-
darone 200 mg, lercanidipine 10 mg, eplerenone 25 mg, 
Table 1. Results of basic laboratory studies during consecutive hospitalisations
Parameter Result Normal
Stay 1 Stay 2 Stay 3
WBC [× 103/μL] 7.30 10.57 6.84 4.00–11.00
RBC [× 106/µL] 5.32 4.38 4.84 4.20–6.10
Hb [g/dL] 15.9 14.2 15.1 14.0–18.0
TC [mmol/L] 3.83 Not determined 5.07 3.00–5.00
LDL [mmol/L] 1.25 Not determined 2.59 < 1.80
HDL [mmol/L] 0.95 Not determined 1.24 > 1.00
TG [mmol/L] 3.58 Not determined 2.73 < 1.70
Glucose [mg/dL] 8.55 8.28 7.97 4.1–5.5
Creatine [µmol/L] 148 150 131.7 59–104.0
eGFR [mL/min/1.73 m2] 46.5 54.44 67 > 60
Na [mmol/L] 136 141 140.1 136–146
K [mmol/L] 4.38 4.30 4.26 3.5–5.1
AspAT [U/L] 34 Not determined 36.7 0–35
AlAT [U/L] 35 30 28.8 0–45
CRP [mg/L] 2.9 8.48 2.8 0–6.0
TSH [µIU/L] 0.672 Not determined 0.588 0.27–4.20
NT-proBNP [pg/mL] 488 Not determined 324.7 < 125
TnT [ng/mL] Not determined Not determined 39 < 14
WBC — white blood count; RBC — red blood count; Hb — haemoglobin; TC — total cholesterol; LDL — low-density lipoproteins; HDL — high-density lipoproteins; TG — triglycerides; eGFR — estimated glomerular 
filtration rate; Na — calcium; K — potasium; AspAT — aspartate aminotransferase; AlAT — alanine aminotransferase; CRP — C-reactive protein; TSH — thyroid-stimulating hormone; NT-proBNP — N-terminal 
pro-B-type natriuretic peptide; TnT — troponin T
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pantoprazole 20 mg, empagliflozin 10 mg, furosemide 
40 mg, torasemide 20 mg, and metformin 3 × 1,000 mg. 
On the above treatment, subsequent control check-ups 
presented a stable clinical picture, with arterial blood pres-
sure of 125/70 mm Hg, fasting glycaemia up to 150 mg/dL, 
and a reduction in body mass of 5 kg. In an ECG there 
was a slight improvement in left ventricular systolic func-
tion (LVEF 28%) and a reduction in LVEDd to 61 mm. In 
ergospirometry with a load of 100 W, the patient achieved 
a VO2 of 12.74 mL/kg/min, respiratory exchange ratio (RER) 
1.16, VO2 anaerobic threshold (AT) 10.42 mL/kg/min. The 
current therapy was maintained. 
Discussion
We present the case of a patient with heart failure and re-
duced ejection fraction of the left ventricle (HFrER) treated 
according to current recommendations with the newest 
therapy for HFrEF, including AT1 receptor antagonists for 
angiotensin II and neprilysin inhibitor (ARNI, angiotensin 
receptor-neprilysin inhibitor) and empagliflozin. Following 
guidelines, empagliflozin has class IIa recommendations 
with a data reliability level of B, and is recommended for 
the prevention or delay of HF and increased lifespan.
Sodium-glucose co-transporter 2 (SGLT2) inhibitors 
are among the newest drug classes for the treatment of 
diabetes. Their mode of action is thought to be linked to 
the renal tubule excretion of glucose into the urine (glyco-
suria) by reducing reverse glucose transport. Owing to the 
regulation of their strength in response to blood glucose 
concentration, the risk of hypoglycaemia with these drugs 
is relatively low, which allows for their combination with 
practically all groups of antidiabetic drugs. The expected 
reduction in levels of glycated haemoglobin over the course 
of using the aforementioned group of drugs is 0.4–0.9 [7]. 
Due to the mechanism of reverse transport, glycosuria is 
accompanied in these patients by natriuresis. Because of 
this, the above medications are characterised by diuretic 
effects, which lead to reduced circulating blood volume, 
decreased body mass (reduced over-hydration), reduced 
arterial blood pressure, and increased haematocrit [8]. 
Moreover, the above group of drugs causes improvements 
in abdominal obesity, uric acid levels, and microalbumi-
nuria [9].
A growing number of publications have shown a positive 
effect of empagliflozin on major adverse cardiac events 
(MACE — defined as death from cardiovascular causes, 
non-lethal strokes or cardiac infarctions) and decreased 
hospitalisations due to HF exacerbations – a result not seen 
with other commonly used diabetes drug groups.
The EMPA-REG OUTCOME study [10] found a 35% 
decrease in the risk of hospitalisation due to exacerbated 
heart failure in the group treated with empagliflozin. Due 
to the fact that the EMPA-REG OUTCOME study was not de-
dicated to an HF population, a further study was designed 
in this patient group to establish the place of empagliflozin 
in the treatment of HF patients. 
The CVD-REAL 2 study [11], comprising over 300,000 pa-
tients with type 2 diabetes from six countries, confirmed 
that the use of drugs from the above group reduces the 
risk of hospitalisation due to exacerbation of heart failure 
as well as mortality. According to the authors of the study, 
a class effect may be possible, as using other SGLT2 inhi-
bitors and not only empagliflozin (making up less than 10% 
Table 2. Selected clinical studies on the effect of sodium-glucose co-transporter 2 (SGLT2) inhibitors on cardiovascular risk
Parameter Name of study
EMPA-REG 
OUTCOME 
[10, 12]
CVD-REAL 2  
[11, 12]
CVD-REAL [12] EASEL [12] CANVAS/ 
/CANVAS-R 
[12]
DECLARE-TIMI 
58 [13]
Type of SGLT2 
inhibitor used
Empagliflozin Dapagliflozin (75%), 
empagliflozin (9%), 
ipragliflozin (8%), 
canagliflozin (4%), 
tofogliflozin (3%), 
luseogliflozin (1%)
Canagliflozin (53%), 
dapagliflozin (42%), 
empagliflozin (5%)
Canagliflozin (58%), 
empagliflozin (26%), 
dapagliflozin (16%)
Canagliflozin Dapagliflozin
Number of  
participants
N > 7,000 N > 400,000 N > 300,000 N > 25,000 N > 10,000 N > 17,000
Heart attack 0.87 
(0.70–1.09)
0.81 
(0.74–0.88)
No data 0.81 
(0.64–1.03)
0.89 
(0.73–1.09)
0.89 
(0.77–1.01)
Stroke 1.18 
(0.89–1.56)
0.68 
(0.55–0.84)
No data 0.85 
(0.66–1.10)
0.87 
(0.69–1.09)
1.01 
(0.84–1.21)
Mortality 0.68 
(0.57–0.82)
0.51 
(0.37–0.70)
0.49 
(0.41–0.57)
0.57 
(0.49–0.66)
0.87 
(0.74–1.01)
0.93 
(0.82–1.04)
Hospitalisation due 
to heart failure
0.65 
(0.50–0.85)
0.64 
(0.50–0.82)
0.61 
(0.51–0.73)
0.57 
(0.45–0.73)
0.67 
(0.52–0.87)
0.73 
(0.61–0.88)
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of the drugs from this group in the above study), confirmed 
the reduction in the number of hospitalisations due to heart 
failure and a reduction in other adverse cardiac events such 
as stroke and cardiac infarction observed in the EMPA-REG 
OUTCOME study. Table 2 shows the most important studies 
on SGLT2 inhibitors conducted so far [10, 12, 13].
The mechanisms behind such a surprising reduction 
in major adverse cardiac events by SGLT2 inhibitors are 
not fully understood. However, it appears obvious that 
they are not caused only by the effects on SGLT2 or due 
to controlling levels of glycaemia, owing to (amongst other 
factors) a low expression of SGLT2 genes on the surface 
of cardiomyocytes, early action of the above drugs on 
important endpoints, and the absence of a correlation 
between levels of glycaemia and glycated haemoglobin 
during control visits, and a reduction in hospitalisations due 
to heart failure. Among the significant factors, the effect 
of these substances on haemostasis in diabetic myocar-
diocytes is often cited. An appropriate Ca2+ concentration 
and rapid changes in its intracellular concentration play 
a key role in transmitting cellular signals, and is therefore 
responsible for the appropriate regulation of cardiac rhythm 
and myocardiocyte contraction. The dynamics of calcium 
levels are affected by sodium levels, which are regulated by 
sodium-potassium pumps or Na+/H+ pumps (NHE). Sodium 
and calcium haemostasis in diabetic patients is dysregu-
lated. Hypoxia, or the increase in intracellular anaerobic 
processes, triggers lactic acid production and a consequent 
decrease of intracellular pH and Na+/H+ pump activation, 
resulting in excessive intracellular sodium [14].
Through a combination of reduced intracellular Na+ 
levels and improved mitochondrial calcium transport, and 
consequently improved myocyte contraction strength, 
SGLT2 inhibitors lead to improved contractile function in 
the heart and reduce parasympathetic nervous system 
activation. This is important in respect of coronary disease-
-afflicted hearts with left ventricle ejection fraction impair-
ment, such as in the patient in our case.
According to another theory, the use of SGLT2 inhibitors 
reduces oxidative stress, which plays an important role in 
maintaining a chronic inflammatory response, apoptosis 
and fibrosis in diabetic patients’ heart muscle, leading to 
unfavourable heart remodelling and fatty acid metabolism 
modification, with a preference for beta-hydroxybutyric acid 
as a substrate, which is the most energetically favourable 
compound [14].
It is also worth mentioning the safety profile of em-
pagliflozin. When used as a monotherapy, it carries a low 
risk of hypoglycaemia. Due to the main hypoglycaemia-
-inducing effect being associated mainly with osmotic 
diuresis, use of this drug requires relatively normal kidney 
function. However, one of the most common complications 
of glycosuria is urogenital infection, with complications of 
urinary tract infections such as pyelonephritis or urosepsis 
occurring with similar frequency in patients taking either 
empagliflozin or a placebo. In this case, no urinary tract 
infections were observed over the course of treatment, 
while body mass reduction and improved glycaemic profile 
were observed, and the medication itself was well tolerated 
by the patient. It is also worth mentioning a different com-
plication that is probably related to lipid oxidation pathway 
alterations, such as ketoacidosis with relatively normal 
glycaemic levels. However, randomised studies have shown 
that such complications are rare in patients not requiring 
insulin therapy [12].
Mechanisms leading to heart failure exacerbations 
mostly have three causes: increased preload, increased 
afterload, and decreased myocardiocyte contractile ability. 
According to the current state of knowledge, SGLT2 inhibi-
tors have multi-targeted effects. They decrease afterload 
Figure 1. Treatment algorithm for a patient with type 2 diabetes and coronary heart disease (based on [12]); BP — blood pressure; ASA — 
acetylsalicylic acid; SGLT2 — sodium glucose co-transporter 2
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Streszczenie
Mężczyznę w wieku 56 lat z ciężką dysfunkcją lewej komory przyjęto na oddział z powodu zaostrzenia objawów przewle-
kłej niewydolności serca z obniżoną frakcją wyrzutową lewej komory. W trakcje hospitalizacji stosowano standardowe 
leczenie niewydolności serca, ale także modyfikowano terapię chorób współistniejących, w tym cukrzycy. Na podstawie 
opisu przypadku klinicznego w artykule przedstawiono aktualny stan wiedzy na temat korzystnego wpływu empagliflo-
zyny na układ sercowo-naczyniowy.
Słowa kluczowe: niewydolność krążenia z obniżona frakcją wyrzutowa lewej komory, empagliflozyna
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through osmotic diuresis and reduce circulating blood 
volume. They also influence sodium and calcium ion hae-
mostasis in cells, thus impacting the force and ‘quality’ of 
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In 2018, a consensus appeared in the US [12] that po-
sitioned SGLT2 inhibitors high in the algorithm for treating 
patients with type 2 diabetes and coronary heart disease. 
SGLT2 inhibitors were recommended to be considered 
in addition to lifestyle change education and metformin 
treatment (Figure 1). 
Conclusions
Empagliflozin is a new therapeutic tool for patients with 
HFrEF with concurrent diabetes. The presented clinical 
case of a patient suffering from multiple concurrent 
conditions implies an important role for empagliflozin 
in HFrEF therapy, which is demonstrated by the exacer-
bation of heart failure necessitating hospitalisation in 
a patient being treated with an optimal standard HFrEF 
therapy with ARNI when administration of empagliflozin 
was stopped. Our case demonstrates the importance 
of the early adoption of novel pharmacotherapies, and 
highlights the need for expert recommendations in eve-
ryday clinical practice.
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